Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apollo Endosurgery, Inc.
Report date April 04, 2023 · Filed April 05, 2023
Jointly reported with Desai Antal Rohit
Section 16 reporting ended · disclosed 2023-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Curlew Fund, LP | 0 |
Reported balance
After 2023-04-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-04-04 · Disposition to issuer · Disposed 675,181 · Balance 0 F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4. F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Killdeer Fund, LP | 0 |
Reported balance
After 2023-04-04 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-04-04 · Disposition to issuer · Disposed 1,310,701 · Balance 0 F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4. F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Roadrunner Fund, LP | 0 |
Reported balance
After 2023-04-04 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2023-04-04 · Disposition to issuer · Disposed 3,687,781 · Balance 0 F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4. F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Crested Crane, LP | 0 |
Reported balance
After 2023-04-04 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2023-04-04 · Disposition to issuer · Disposed 45,594 · Balance 0 F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4. F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Kestrel Fund, LP | 0 |
Reported balance
After 2023-04-04 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2023-04-04 · Disposition to issuer · Disposed 63,671 · Balance 0 F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4. F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Mallard Fund, LP | 0 |
Reported balance
After 2023-04-04 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2023-04-04 · Disposition to issuer · Disposed 400,675 · Balance 0 F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4. F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4.
F2: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
F3: Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions.
PROCEPT BioRobotics Corp
Report date May 03, 2024 · Filed May 07, 2024
Jointly reported with McGaughy R Kent Jr, White Tailed Ptarmigan, LP
Section 16 reporting ended · disclosed 2024-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy White Tailed Ptarmigan, LP | 2,823,681 |
Reported balance
After 2024-05-03 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-05-03 · Other · Disposed 1,785,127 · Balance 2,823,681 F2: On May 3, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 421,061 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. F1: CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). In such capacities, CPMG, Inc. may be deemed to have voting and investment control over the shares beneficially owned by the CPMG Funds. Antal Desai, a member of the Issuer's board of directors, and Kent McGaughy, Jr., each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Antal Desai reports his beneficial ownership of these shares on a separate Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy Kestrel Fund, L.P. | 54,037 |
Reported balance
Holding disclosure · report date 2024-05-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 54,037 F3: Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on May 3, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. F1: CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). In such capacities, CPMG, Inc. may be deemed to have voting and investment control over the shares beneficially owned by the CPMG Funds. Antal Desai, a member of the Issuer's board of directors, and Kent McGaughy, Jr., each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Antal Desai reports his beneficial ownership of these shares on a separate Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy Mallard Fund, L.P. | 344,627 |
Reported balance
Holding disclosure · report date 2024-05-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 344,627 F3: Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on May 3, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. F1: CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). In such capacities, CPMG, Inc. may be deemed to have voting and investment control over the shares beneficially owned by the CPMG Funds. Antal Desai, a member of the Issuer's board of directors, and Kent McGaughy, Jr., each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Antal Desai reports his beneficial ownership of these shares on a separate Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy Lagos Trust | 553,592 |
Reported balance
Holding disclosure · report date 2024-05-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 553,592 F3: Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on May 3, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. F4: Mr. McGaughy, Jr. is a trustee of Lagos Trust. Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by Lagos Trust except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 4,523 |
Reported balance
Holding disclosure · report date 2024-05-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 4,523 F3: Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on May 3, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. |
Filing footnotes · ownership attribution and instrument terms
F1: CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). In such capacities, CPMG, Inc. may be deemed to have voting and investment control over the shares beneficially owned by the CPMG Funds. Antal Desai, a member of the Issuer's board of directors, and Kent McGaughy, Jr., each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Antal Desai reports his beneficial ownership of these shares on a separate Form 4.
F2: On May 3, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 421,061 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13.
F3: Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on May 3, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13.
F4: Mr. McGaughy, Jr. is a trustee of Lagos Trust. Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by Lagos Trust except to the extent of any pecuniary interest therein.
REATA PHARMACEUTICALS INC
Report date September 26, 2023 · Filed September 28, 2023
Jointly reported with Desai Antal Rohit
Section 16 reporting ended · disclosed 2023-09-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | IndirectBy The 2:22 DNA Trust | 0 |
Reported balance
After 2023-09-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-09-26 · Disposition to issuer · Disposed 31,467 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F1: Mr. Desai and his spouse serve as co-trustees of The 2:22 DNA Trust. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy CPMG, Inc. | 0 |
Reported balance
After 2023-09-26 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-09-26 · Disposition to issuer · Disposed 113 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Nighthawk Partners, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2023-09-26 · Disposition to issuer · Disposed 116,512 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Willet Fund, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2023-09-26 · Disposition to issuer · Disposed 282,246 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Killdeer Fund, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2023-09-26 · Disposition to issuer · Disposed 137,962 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Elepaio Partners, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2023-09-26 · Disposition to issuer · Disposed 5,464 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Barred Owl Partners, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2023-09-26 · Disposition to issuer · Disposed 44,200 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Managed Account for Trustees of the University of Pennsylvania | 0 |
Reported balance
After 2023-09-26 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2023-09-26 · Disposition to issuer · Disposed 34,897 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Gallopavo, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2023-09-26 · Disposition to issuer · Disposed 442,560 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Roadrunner Fund, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2023-09-26 · Disposition to issuer · Disposed 748,253 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Yellow Warbler, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2023-09-26 · Disposition to issuer · Disposed 431,155 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Mallard Fund, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 12
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 12 · 2023-09-26 · Disposition to issuer · Disposed 109,415 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Crested Crane, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 13
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 13 · 2023-09-26 · Disposition to issuer · Disposed 37,909 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Sandpiper Fund, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 14
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 14 · 2023-09-26 · Disposition to issuer · Disposed 334,740 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Kestrel Fund, LP( | 0 |
Reported balance
After 2023-09-26 transaction · row 15
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 15 · 2023-09-26 · Disposition to issuer · Disposed 160,265 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy CD Fund, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 16
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 16 · 2023-09-26 · Disposition to issuer · Disposed 11,076 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class A common stockSEC Table I · non-derivative | IndirectBy Redbird Life Sciences Partners, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 17
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 17 · 2023-09-26 · Disposition to issuer · Disposed 134 · Balance 0 F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class B common stockSEC Table II · derivative / convertible security | IndirectBy CPMG, Inc. | 0 |
Reported balance
After 2023-09-26 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2023-09-26 · Disposition to issuer · Disposed 1,251 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class B common stockSEC Table II · derivative / convertible security | IndirectBy Mallard Fund, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2023-09-26 · Disposition to issuer · Disposed 150,186 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class B common stockSEC Table II · derivative / convertible security | IndirectBy Kestrel Fund, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2023-09-26 · Disposition to issuer · Disposed 307,776 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class B common stockSEC Table II · derivative / convertible security | IndirectBy CD Fund, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2023-09-26 · Disposition to issuer · Disposed 123,279 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class B common stockSEC Table II · derivative / convertible security | IndirectBy Redbird Life Sciences Partners, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2023-09-26 · Disposition to issuer · Disposed 1,490 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class B common stockSEC Table II · derivative / convertible security | IndirectBy Willet Fund, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2023-09-26 · Disposition to issuer · Disposed 114,946 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
| Class B common stockSEC Table II · derivative / convertible security | IndirectBy Yellow Warbler, LP | 0 |
Reported balance
After 2023-09-26 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2023-09-26 · Disposition to issuer · Disposed 993,929 · Balance 0 F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date. F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes. F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4. F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Desai and his spouse serve as co-trustees of The 2:22 DNA Trust.
F2: CPMG, Inc. is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania (collectively, the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the securities held directly by CPMG, Inc. and the Funds. Mr. McGaughy, Jr. reports his beneficial ownership of these securities on a separate Form 4.
F3: Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
F4: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, each of the Issuer's outstanding shares of Class A common stock and Class B common stock was canceled and extinguished and automatically converted into the right to receive $172.50 in cash, without interest, less any withholding taxes.
F5: The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2021 Filed Sep 21, 2021 18:34 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | ConversionCommon Stock | 10,084,910 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-21-018953 · wf-form4_163226365231972.xml · nonDerivative · entry 1 CPMG Inc · CIK 0001372218 · 10% owner McGaughy R Kent Jr · CIK 0001402856 · 10% owner White Tailed Ptarmigan, LP · CIK 0001882743 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By White Tailed Ptarmigan, LP Disclosed balance after: 10,782,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. F2 · ownership.nature: CPMG, Inc. is the general partner of White Tailed Ptarmigan, LP and has voting and investment control over the shares beneficially owned by White Tailed Ptarmigan, LP. Antal Desai, a member of our board of directors and a Partner of CPMG, Inc., along with Kent McGaughy, Jr., the sole shareholder and managing director of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by White Tailed Ptarmigan, LP. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by White Tailed Ptarmigan, LP except to the extent of any pecuniary interest therein. Antal Desai is separately reporting his deemed indirect ownership of the shares held by White Tailed Ptarmigan, LP. Read SEC document |
| December 23, 2020 Filed Dec 29, 2020 17:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | OtherClass A common stock | 103,185 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-20-029804 · form4.xml · nonDerivative · entry 2 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Blackwell Partners LLC Disclosed balance after: 0 F3 · kind: The transaction represents the revocation of the Reporting Person's investment discretion with respect to the shares held by the Blackwell Account. No distribution or sale of shares was made by the Reporting Person in connection with the transaction. The transaction reflects 2.2% of the 4,756,424 Class A and Class B shares of the issuer beneficially owned by the Reporting Person prior to the date of the transaction. F3 · price: The transaction represents the revocation of the Reporting Person's investment discretion with respect to the shares held by the Blackwell Account. No distribution or sale of shares was made by the Reporting Person in connection with the transaction. The transaction reflects 2.2% of the 4,756,424 Class A and Class B shares of the issuer beneficially owned by the Reporting Person prior to the date of the transaction. F3 · balance_after: The transaction represents the revocation of the Reporting Person's investment discretion with respect to the shares held by the Blackwell Account. No distribution or sale of shares was made by the Reporting Person in connection with the transaction. The transaction reflects 2.2% of the 4,756,424 Class A and Class B shares of the issuer beneficially owned by the Reporting Person prior to the date of the transaction. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania and a managed account of Blackwell Partners LLC - Series A (the "Blackwell Account"). The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania and a managed account of Blackwell Partners LLC - Series A (the "Blackwell Account"). The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 23, 2020 Filed Dec 29, 2020 17:35 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | OtherClass A common stock | 63,481 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-20-029804 · form4.xml · nonDerivative · entry 1 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Flamingo Fund, LP Disclosed balance after: 0 F2 · kind: The transaction represents the distribution of shares by Flamingo Fund, LP to its sole limited partner. No sale of shares was made by the Reporting Person or Flamingo Fund, LP in connection with the transaction. The transaction reflects 1.3% of the 4,756,424 Class A and Class B shares of the issuer beneficially owned by the Reporting Person prior to the date of the transaction. F2 · price: The transaction represents the distribution of shares by Flamingo Fund, LP to its sole limited partner. No sale of shares was made by the Reporting Person or Flamingo Fund, LP in connection with the transaction. The transaction reflects 1.3% of the 4,756,424 Class A and Class B shares of the issuer beneficially owned by the Reporting Person prior to the date of the transaction. F2 · balance_after: The transaction represents the distribution of shares by Flamingo Fund, LP to its sole limited partner. No sale of shares was made by the Reporting Person or Flamingo Fund, LP in connection with the transaction. The transaction reflects 1.3% of the 4,756,424 Class A and Class B shares of the issuer beneficially owned by the Reporting Person prior to the date of the transaction. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania and a managed account of Blackwell Partners LLC - Series A (the "Blackwell Account"). The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; Elepaio Partners, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; a managed account for Trustees of the University of Pennsylvania and a managed account of Blackwell Partners LLC - Series A (the "Blackwell Account"). The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 18:39 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | PurchaseClass A common stock | 1,200,000 | $1.25 | $1,500,000.00 |
DisclosureSEC source: 0000905148-20-000825 · form4.xml · nonDerivative · entry 3 CPMG Inc · CIK 0001372218 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roadrunner Fund, LP Disclosed balance after: 1,707,208 F2 · kind: These shares were acquired directly from the Issuer pursuant to a securities purchase agreement dated as of July 17, 2020. F2 · price: These shares were acquired directly from the Issuer pursuant to a securities purchase agreement dated as of July 17, 2020. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 18:39 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | PurchaseClass A common stock | 400,000 | $1.25 | $500,000.00 |
DisclosureSEC source: 0000905148-20-000825 · form4.xml · nonDerivative · entry 2 CPMG Inc · CIK 0001372218 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Killdeer Fund, LP Disclosed balance after: 415,244 F2 · kind: These shares were acquired directly from the Issuer pursuant to a securities purchase agreement dated as of July 17, 2020. F2 · price: These shares were acquired directly from the Issuer pursuant to a securities purchase agreement dated as of July 17, 2020. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 18:39 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | PurchaseClass A common stock | 180,000 | $1.25 | $225,000.00 |
DisclosureSEC source: 0000905148-20-000825 · form4.xml · nonDerivative · entry 1 CPMG Inc · CIK 0001372218 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Curlew Fund, LP Disclosed balance after: 477,120 F2 · kind: These shares were acquired directly from the Issuer pursuant to a securities purchase agreement dated as of July 17, 2020. F2 · price: These shares were acquired directly from the Issuer pursuant to a securities purchase agreement dated as of July 17, 2020. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 18:27 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | OtherClass A common stock | 38,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-20-000329 · form4.xml · nonDerivative · entry 3 CPMG Inc · CIK 0001372218 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roadrunner Fund, LP Disclosed balance after: 507,208 F2 · kind: Pursuant to the terms of the Issuer's 6.0% Convertible Debentures due 2024 ("Notes"), the semi-annual interest payment due on the Notes was paid by the Issuer in shares of the Issuer's common stock, based on the interest rate of 6.00% per year and the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the interest payment date. F2 · price: Pursuant to the terms of the Issuer's 6.0% Convertible Debentures due 2024 ("Notes"), the semi-annual interest payment due on the Notes was paid by the Issuer in shares of the Issuer's common stock, based on the interest rate of 6.00% per year and the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the interest payment date. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 18:27 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | OtherClass A common stock | 15,244 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-20-000329 · form4.xml · nonDerivative · entry 2 CPMG Inc · CIK 0001372218 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Killdeer Fund, LP Disclosed balance after: 15,244 F2 · kind: Pursuant to the terms of the Issuer's 6.0% Convertible Debentures due 2024 ("Notes"), the semi-annual interest payment due on the Notes was paid by the Issuer in shares of the Issuer's common stock, based on the interest rate of 6.00% per year and the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the interest payment date. F2 · price: Pursuant to the terms of the Issuer's 6.0% Convertible Debentures due 2024 ("Notes"), the semi-annual interest payment due on the Notes was paid by the Issuer in shares of the Issuer's common stock, based on the interest rate of 6.00% per year and the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the interest payment date. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 18:27 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | OtherClass A common stock | 3,811 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-20-000329 · form4.xml · nonDerivative · entry 1 CPMG Inc · CIK 0001372218 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Curlew Fund, LP Disclosed balance after: 297,120 F2 · kind: Pursuant to the terms of the Issuer's 6.0% Convertible Debentures due 2024 ("Notes"), the semi-annual interest payment due on the Notes was paid by the Issuer in shares of the Issuer's common stock, based on the interest rate of 6.00% per year and the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the interest payment date. F2 · price: Pursuant to the terms of the Issuer's 6.0% Convertible Debentures due 2024 ("Notes"), the semi-annual interest payment due on the Notes was paid by the Issuer in shares of the Issuer's common stock, based on the interest rate of 6.00% per year and the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the interest payment date. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 17:20 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 5,464 | $183.00 | $999,912.00 |
DisclosureSEC source: 0000905148-19-001001 · form4.xml · nonDerivative · entry 4 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Elepaio Partners, LP Disclosed balance after: 5,464 F1 · ownership.direct: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Killdeer Fund, LP; Willet Fund, LP; Elepaio Partners, LP; Barred Owl Partners, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Killdeer Fund, LP; Willet Fund, LP; Elepaio Partners, LP; Barred Owl Partners, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 17:20 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 27,322 | $183.00 | $4,999,926.00 |
DisclosureSEC source: 0000905148-19-001001 · form4.xml · nonDerivative · entry 3 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Killdeer Fund, LP Disclosed balance after: 137,962 F1 · ownership.direct: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Killdeer Fund, LP; Willet Fund, LP; Elepaio Partners, LP; Barred Owl Partners, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Killdeer Fund, LP; Willet Fund, LP; Elepaio Partners, LP; Barred Owl Partners, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 17:20 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 328 | $183.00 | $60,024.00 |
DisclosureSEC source: 0000905148-19-001001 · form4.xml · nonDerivative · entry 2 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Willet Fund, LP Disclosed balance after: 282,246 F1 · ownership.direct: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Killdeer Fund, LP; Willet Fund, LP; Elepaio Partners, LP; Barred Owl Partners, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Killdeer Fund, LP; Willet Fund, LP; Elepaio Partners, LP; Barred Owl Partners, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 17:20 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 7,104 | $183.00 | $1,300,032.00 |
DisclosureSEC source: 0000905148-19-001001 · form4.xml · nonDerivative · entry 1 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Nighthawk Partners, LP Disclosed balance after: 116,512 F1 · ownership.direct: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Killdeer Fund, LP; Willet Fund, LP; Elepaio Partners, LP; Barred Owl Partners, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Killdeer Fund, LP; Willet Fund, LP; Elepaio Partners, LP; Barred Owl Partners, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 12, 2018 Filed Dec 12, 2018 17:57 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 1,418 | $59.90 | $84,931.39 |
DisclosureSEC source: 0000905148-18-000920 · form4.xml · nonDerivative · entry 5 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Willet Fund, LP Disclosed balance after: 281,918 F6 · price: This price reflects the weighted average purchase price for open-market purchases on December 12, 2018, within a $1.00 range. The actual prices for these transactions range from $59.84 to $59.98, inclusive. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 17:57 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 52,809 | $60.07 | $3,172,336.97 |
DisclosureSEC source: 0000905148-18-000920 · form4.xml · nonDerivative · entry 4 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Nighthawk Partners, LP Disclosed balance after: 109,408 F5 · price: This price reflects the weighted average purchase price for open-market purchases on December 11, 2018, within a $1.00 range. The actual prices for these transactions range from $59.52 to $60.145, inclusive. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:57 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 29,347 | $59.53 | $1,747,035.71 |
DisclosureSEC source: 0000905148-18-000920 · form4.xml · nonDerivative · entry 3 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Nighthawk Partners, LP Disclosed balance after: 56,599 F4 · price: This price reflects the weighted average purchase price for open-market purchases on December 10, 2018, within a $1.00 range. The actual prices for these transactions range from $59.24 to $59.80, inclusive. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:57 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 1,078 | $58.62 | $63,194.30 |
DisclosureSEC source: 0000905148-18-000920 · form4.xml · nonDerivative · entry 2 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Nighthawk Partners, LP Disclosed balance after: 27,252 F3 · price: This price reflects the weighted average purchase price for open-market purchases on December 10, 2018, within a $1.00 range. The actual prices for these transactions range from $58.235 to $59.17, inclusive. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:57 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 26,174 | $57.93 | $1,516,335.72 |
DisclosureSEC source: 0000905148-18-000920 · form4.xml · nonDerivative · entry 1 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Nighthawk Partners, LP Disclosed balance after: 26,174 F2 · price: This price reflects the weighted average purchase price for open-market purchases on December 10, 2018, within a $1.00 range. The actual prices for these transactions range from $57.235 to $58.23, inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. F1 · ownership.direct: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The Reporting Person is the investment manager of each of: Nighthawk Partners, LP; Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:03 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 17,000 | $28.47 | $484,015.50 |
DisclosureSEC source: 0001140361-17-047821 · form4.xml · nonDerivative · entry 1 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Barred Owl Partners, LP Disclosed balance after: 44,200 F1 · price: This price reflects the weighted average purchase price for open-market purchases on December 29, 2017, within a $1.00 range. The actual prices for these transactions range from $28.40 to $28.50 inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.direct: The Reporting Person is the investment manager of each of: Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 28, 2017 Filed Dec 28, 2017 18:53 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 200 | $26.10 | $5,220.00 |
DisclosureSEC source: 0001140361-17-047647 · form4.xml · nonDerivative · entry 3 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Barred Owl Partners, LP Disclosed balance after: 27,200 F3 · ownership.direct: The Reporting Person is the investment manager of each of: Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.nature: The Reporting Person is the investment manager of each of: Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 27, 2017 Filed Dec 28, 2017 18:53 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 15,000 | $25.83 | $387,444.00 |
DisclosureSEC source: 0001140361-17-047647 · form4.xml · nonDerivative · entry 2 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Barred Owl Partners, LP Disclosed balance after: 27,000 F2 · price: This price reflects the weighted average purchase price for open-market purchases on December 27, 2017, within a $1.00 range. The actual prices for these transactions range from $25.595 to $26.00 inclusive. F3 · ownership.direct: The Reporting Person is the investment manager of each of: Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.nature: The Reporting Person is the investment manager of each of: Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 26, 2017 Filed Dec 28, 2017 18:53 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 12,000 | $26.06 | $312,726.00 |
DisclosureSEC source: 0001140361-17-047647 · form4.xml · nonDerivative · entry 1 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Barred Owl Partners, LP Disclosed balance after: 12,000 F1 · price: This price reflects the weighted average purchase price for open-market purchases on December 26, 2017, within a $1.00 range. The actual prices for these transactions range from $25.72 to $26.14 inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F3 · ownership.direct: The Reporting Person is the investment manager of each of: Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.nature: The Reporting Person is the investment manager of each of: Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 18:38 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 37,492 | $24.65 | $924,282.78 |
DisclosureSEC source: 0000905148-17-000939 · form4.xml · nonDerivative · entry 12 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Yellow Warbler, LP Disclosed balance after: 431,155 F3 · price: This price reflects the weighted average purchase price for open-market purchases on December 14, 2017, within a $1.00 range. The actual prices for these transactions range from $24.40 to $24.92, inclusive. F5 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F5 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 18:38 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 6,245 | $24.65 | $153,956.74 |
DisclosureSEC source: 0000905148-17-000939 · form4.xml · nonDerivative · entry 9 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Blackwell Partners LLC Disclosed balance after: 103,185 F3 · price: This price reflects the weighted average purchase price for open-market purchases on December 14, 2017, within a $1.00 range. The actual prices for these transactions range from $24.40 to $24.92, inclusive. F5 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F5 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 18:38 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 19,672 | $24.65 | $484,969.88 |
DisclosureSEC source: 0000905148-17-000939 · form4.xml · nonDerivative · entry 6 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roadrunner Fund, LP Disclosed balance after: 748,253 F3 · price: This price reflects the weighted average purchase price for open-market purchases on December 14, 2017, within a $1.00 range. The actual prices for these transactions range from $24.40 to $24.92, inclusive. F5 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F5 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 18:38 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 14,866 | $24.65 | $366,488.52 |
DisclosureSEC source: 0000905148-17-000939 · form4.xml · nonDerivative · entry 3 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Gallopavo, LP Disclosed balance after: 477,457 F3 · price: This price reflects the weighted average purchase price for open-market purchases on December 14, 2017, within a $1.00 range. The actual prices for these transactions range from $24.40 to $24.92, inclusive. F5 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F5 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 14, 2017 Filed Dec 28, 2017 18:38 UTC Amendment | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 14,866 | $24.65 | $366,488.52 |
DisclosureSEC source: 0001140361-17-047643 · form4.xml · nonDerivative · entry 3 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Managed Account for Trustees of the University of Pennsylvania Disclosed balance after: 34,897 F5 · shares: On December 15, 2017, the Reporting Persons inadvertently reported that these shares were purchased for the account of Gallopavo, LP. As correctly noted on this amendment, the shares were purchased for a managed account for Trustees of the University of Pennsylvania. Gallopavo, LP has not engaged in trades since the report filed by the Reporting Persons on June 23, 2017. F3 · price: This price reflects the weighted average purchase price for open-market purchases on December 14, 2017, within a $1.00 range. The actual prices for these transactions range from $24.40 to $24.92, inclusive. F4 · ownership.direct: The Reporting Person is the investment manager of each of Gallopavo, LP and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.nature: The Reporting Person is the investment manager of each of Gallopavo, LP and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 18:38 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 148 | $23.98 | $3,548.55 |
DisclosureSEC source: 0000905148-17-000939 · form4.xml · nonDerivative · entry 11 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Yellow Warbler, LP Disclosed balance after: 393,663 F2 · price: This price reflects the weighted average purchase price for open-market purchases on December 13, 2017, within a $1.00 range. The actual prices for these transactions range from $23.97 to $23.99 inclusive. F5 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F5 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 18:38 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 59,982 | $24.88 | $1,492,580.09 |
DisclosureSEC source: 0000905148-17-000939 · form4.xml · nonDerivative · entry 10 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Yellow Warbler, LP Disclosed balance after: 393,515 F1 · price: This price reflects the weighted average purchase price for open-market purchases on December 13, 2017, within a $1.00 range. The actual prices for these transactions range from $24.08 to $25.08 inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. F5 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F5 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 18:38 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 25 | $23.98 | $599.42 |
DisclosureSEC source: 0000905148-17-000939 · form4.xml · nonDerivative · entry 8 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Blackwell Partners LLC Disclosed balance after: 96,940 F2 · price: This price reflects the weighted average purchase price for open-market purchases on December 13, 2017, within a $1.00 range. The actual prices for these transactions range from $23.97 to $23.99 inclusive. F5 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F5 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 18:38 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 9,990 | $24.88 | $248,589.16 |
DisclosureSEC source: 0000905148-17-000939 · form4.xml · nonDerivative · entry 7 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Blackwell Partners LLC Disclosed balance after: 96,915 F1 · price: This price reflects the weighted average purchase price for open-market purchases on December 13, 2017, within a $1.00 range. The actual prices for these transactions range from $24.08 to $25.08 inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. F5 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F5 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 18:38 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 78 | $23.98 | $1,870.18 |
DisclosureSEC source: 0000905148-17-000939 · form4.xml · nonDerivative · entry 5 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roadrunner Fund, LP Disclosed balance after: 728,581 F2 · price: This price reflects the weighted average purchase price for open-market purchases on December 13, 2017, within a $1.00 range. The actual prices for these transactions range from $23.97 to $23.99 inclusive. F5 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F5 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 18:38 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 31,471 | $24.88 | $783,118.07 |
DisclosureSEC source: 0000905148-17-000939 · form4.xml · nonDerivative · entry 4 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roadrunner Fund, LP Disclosed balance after: 728,503 F1 · price: This price reflects the weighted average purchase price for open-market purchases on December 13, 2017, within a $1.00 range. The actual prices for these transactions range from $24.08 to $25.08 inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. F5 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F5 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 18:38 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 49 | $23.98 | $1,174.86 |
DisclosureSEC source: 0000905148-17-000939 · form4.xml · nonDerivative · entry 2 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Gallopavo, LP Disclosed balance after: 462,591 F2 · price: This price reflects the weighted average purchase price for open-market purchases on December 13, 2017, within a $1.00 range. The actual prices for these transactions range from $23.97 to $23.99 inclusive. F5 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F5 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 18:38 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 19,982 | $24.88 | $497,228.09 |
DisclosureSEC source: 0000905148-17-000939 · form4.xml · nonDerivative · entry 1 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Gallopavo, LP Disclosed balance after: 462,542 F1 · price: This price reflects the weighted average purchase price for open-market purchases on December 13, 2017, within a $1.00 range. The actual prices for these transactions range from $24.08 to $25.08 inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. F5 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F5 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 13, 2017 Filed Dec 28, 2017 18:38 UTC Amendment | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 49 | $23.98 | $1,174.86 |
DisclosureSEC source: 0001140361-17-047643 · form4.xml · nonDerivative · entry 2 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Managed Account for Trustees of the University of Pennsylvania Disclosed balance after: 20,031 F5 · shares: On December 15, 2017, the Reporting Persons inadvertently reported that these shares were purchased for the account of Gallopavo, LP. As correctly noted on this amendment, the shares were purchased for a managed account for Trustees of the University of Pennsylvania. Gallopavo, LP has not engaged in trades since the report filed by the Reporting Persons on June 23, 2017. F2 · price: This price reflects the weighted average purchase price for open-market purchases on December 13, 2017, within a $1.00 range. The actual prices for these transactions range from $23.97 to $23.99 inclusive. F4 · ownership.direct: The Reporting Person is the investment manager of each of Gallopavo, LP and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.nature: The Reporting Person is the investment manager of each of Gallopavo, LP and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 13, 2017 Filed Dec 28, 2017 18:38 UTC Amendment | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass A common stock | 19,982 | $24.88 | $497,228.09 |
DisclosureSEC source: 0001140361-17-047643 · form4.xml · nonDerivative · entry 1 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Managed Account for Trustees of the University of Pennsylvania Disclosed balance after: 19,982 F5 · shares: On December 15, 2017, the Reporting Persons inadvertently reported that these shares were purchased for the account of Gallopavo, LP. As correctly noted on this amendment, the shares were purchased for a managed account for Trustees of the University of Pennsylvania. Gallopavo, LP has not engaged in trades since the report filed by the Reporting Persons on June 23, 2017. F1 · price: This price reflects the weighted average purchase price for open-market purchases on December 13, 2017, within a $1.00 range. The actual prices for these transactions range from $24.08 to $25.08 inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. F4 · ownership.direct: The Reporting Person is the investment manager of each of Gallopavo, LP and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.nature: The Reporting Person is the investment manager of each of Gallopavo, LP and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B Common Stock · Derivative | 110,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · derivative · entry 24 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Killdeer Fund, LP Disclosed balance after: 0 Underlying: Class A Common Stock · 110,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · derivative.exercise_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · derivative.expiration_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B Common Stock · Derivative | 33,656 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · derivative · entry 23 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Blackwell Partners LLC - Series A Disclosed balance after: 0 Underlying: Class A Common Stock · 33,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · derivative.exercise_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · derivative.expiration_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B Common Stock · Derivative | 386,285 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · derivative · entry 22 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roadrunner Fund, LP Disclosed balance after: 0 Underlying: Class A Common Stock · 386,285 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · derivative.exercise_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · derivative.expiration_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B Common Stock · Derivative | 211,708 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · derivative · entry 21 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Gallopavo, LP Disclosed balance after: 0 Underlying: Class A Common Stock · 211,708 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · derivative.exercise_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · derivative.expiration_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass B Common Stock · Derivative | 110,640 | $25.00 | $2,766,000.00 |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · derivative · entry 20 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Killdeer Fund, LP Disclosed balance after: 110,640 Underlying: Class A Common Stock · 110,640 shares Expires not disclosed F4 · derivative.exercise_price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F3 · price: These shares of Class B common stock were acquired in a private transaction with another Class B shareholder pursuant to a purchase agreement dated June 22, 2017 (the "Private Transaction"). F4 · derivative.exercise_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · derivative.expiration_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass B Common Stock · Derivative | 33,656 | $25.00 | $841,400.00 |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · derivative · entry 19 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Blackwell Partners LLC - Series A Disclosed balance after: 33,656 Underlying: Class A Common Stock · 33,656 shares Expires not disclosed F4 · derivative.exercise_price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F3 · price: These shares of Class B common stock were acquired in a private transaction with another Class B shareholder pursuant to a purchase agreement dated June 22, 2017 (the "Private Transaction"). F4 · derivative.exercise_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · derivative.expiration_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass B Common Stock · Derivative | 386,285 | $25.00 | $9,657,125.00 |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · derivative · entry 18 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roadrunner Fund, LP Disclosed balance after: 386,285 Underlying: Class A Common Stock · 386,285 shares Expires not disclosed F4 · derivative.exercise_price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F3 · price: These shares of Class B common stock were acquired in a private transaction with another Class B shareholder pursuant to a purchase agreement dated June 22, 2017 (the "Private Transaction"). F4 · derivative.exercise_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · derivative.expiration_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass B Common Stock · Derivative | 211,708 | $25.00 | $5,292,700.00 |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · derivative · entry 17 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Gallopavo, LP Disclosed balance after: 211,708 Underlying: Class A Common Stock · 211,708 shares Expires not disclosed F4 · derivative.exercise_price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F3 · price: These shares of Class B common stock were acquired in a private transaction with another Class B shareholder pursuant to a purchase agreement dated June 22, 2017 (the "Private Transaction"). F4 · derivative.exercise_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F4 · derivative.expiration_date: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass B Common Stock · Derivative | 355,591 | $25.00 | $8,889,775.00 |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · derivative · entry 16 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Yellow Warbler, LP Disclosed balance after: 993,929 Underlying: Class A Common Stock · 355,591 shares Expires not disclosed F1 · derivative.exercise_price: These shares of Class B common stock are convertible into Class A common stock on a one-for-one basis at the holder's election at any time for no additional consideration, and have no expiration date. F3 · price: These shares of Class B common stock were acquired in a private transaction with another Class B shareholder pursuant to a purchase agreement dated June 22, 2017 (the "Private Transaction"). F1 · derivative.exercise_date: These shares of Class B common stock are convertible into Class A common stock on a one-for-one basis at the holder's election at any time for no additional consideration, and have no expiration date. F1 · derivative.expiration_date: These shares of Class B common stock are convertible into Class A common stock on a one-for-one basis at the holder's election at any time for no additional consideration, and have no expiration date. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | PurchaseClass B Common Stock · Derivative | 102,120 | $25.00 | $2,553,000.00 |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · derivative · entry 15 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Willet Fund, LP Disclosed balance after: 114,946 Underlying: Class A Common Stock · 102,120 shares Expires not disclosed F1 · derivative.exercise_price: These shares of Class B common stock are convertible into Class A common stock on a one-for-one basis at the holder's election at any time for no additional consideration, and have no expiration date. F3 · price: These shares of Class B common stock were acquired in a private transaction with another Class B shareholder pursuant to a purchase agreement dated June 22, 2017 (the "Private Transaction"). F1 · derivative.exercise_date: These shares of Class B common stock are convertible into Class A common stock on a one-for-one basis at the holder's election at any time for no additional consideration, and have no expiration date. F1 · derivative.expiration_date: These shares of Class B common stock are convertible into Class A common stock on a one-for-one basis at the holder's election at any time for no additional consideration, and have no expiration date. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 110,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · nonDerivative · entry 4 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Killdeer Fund, LP Disclosed balance after: 110,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F2 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 33,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · nonDerivative · entry 3 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Blackwell Partners LLC - Series A Disclosed balance after: 86,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F2 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 17:54 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 386,285 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-17-000624 · form4.xml · nonDerivative · entry 2 CPMG Inc · CIK 0001372218 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roadrunner Fund, LP Disclosed balance after: 697,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Because none of Blackwell Partners LLC - Series A, Gallopavo, LP, Roadrunner Fund, LP and Killdeer Fund, LP were holders of shares of Class B common stock at the time of the Private Transaction, then, pursuant to Section 4.4(b) of the Issuer's Thirteenth Amended and Restated Certificate of Incorporation, these shares of Class B common stock automatically convert into shares of Class A common stock in connection with the Private Transaction, on a one-for-one basis and for no additional consideration. F2 · ownership.direct: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.nature: The Reporting Person is the investment manager of each of: Killdeer Fund, LP; Blackwell Partners LLC - Series A; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.